Form 8-K - Current report:
SEC Accession No. 0001827506-25-000072
Filing Date
2025-06-06
Accepted
2025-06-06 16:06:36
Documents
12
Period of Report
2025-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K trml-20250604.htm   iXBRL 8-K 35877
  Complete submission text file 0001827506-25-000072.txt   159152

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trml-20250604.xsd EX-101.SCH 1800
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trml-20250604_lab.xml EX-101.LAB 23449
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trml-20250604_pre.xml EX-101.PRE 13593
14 EXTRACTED XBRL INSTANCE DOCUMENT trml-20250604_htm.xml XML 2915
Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 251030632
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)